Application of the Belle.AI Dermatological Image Reference System for Patient Diagnosis in an Active Clinical Setting

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorBelleTorus Corporation

About this trial

The goal of this research study is to test a new, investigational tool that uses artificial intelligence (AI) to help primary care providers assess skin conditions. This tool is an AI-powered dermatology image reference app that works with a smartphone. For clarity, the AI makes no diagnoses; it provides reference images. Primary care providers then use their own medical judgement and training to make the diagnosis.

The sponsor aims to compare the diagnoses made by primary care providers (such as doctors, nurse practitioners, and physician assistants) with the support of the AI tool compared to a panel of dermatologists, who are setting the gold standard. By doing so, the sponsor can determine the value of the AI tool for primary care providers and understand how it might be used alongside traditional clinical care.

This AI capability complies with FDA regulatory guidelines and is not considered a medical device, similar to a Google image search, which returns similar looking images for reference purposes. For intervention, they healthcare providers use their own training and clinical judgement to make the diagnosis, and not the AI.

Eligibility criteria

Qualifiers

Patient must present to walk-in clinic with a primary dermatological complaint.

Patient must have the ability and willingness to provide informed consent and comply with study procedures and visits.

Participants must have access to the required technology (e.g., smartphone with internet access) and be capable of using it for the required image capture.

Disqualifiers

Patients who are unable to comply with study procedures due to physical or mental health limitations (as assessed by study coordinator).

Pediatric, adolescent, and teen patients who present with dermatological conditions on their genitalia will not be included in the study (in support of patient privacy concerns).

Trial design

Treatments tested in this trial

  • Dermatology/Skin - Other

Treatment groups

263 Participants
are divided into 1 treatment group

Sponsors and collaborators

BelleTorus Corporation

Lead sponsor

Urban Health Plan Inc.

Collaborator